Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -68.60% is in line with its 5-year average of -65.75%, around the middle of its 5-year range (-141.98%–-29.76%).
44.76% above its 12-month average of -124.17%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.74%.
RETURN ON ASSETS (ROA)
-68.60%
RETURN ON ASSETS (ROA) AVG TTM
-124.17%
RETURN ON ASSETS (ROA) AVG 3Y
-83.59%
RETURN ON ASSETS (ROA) AVG 5Y
-65.75%
RETURN ON ASSETS (ROA) AVG 10Y
-88.60%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+44.76%
CURRENT VS 3Y AVG
+17.93%
CURRENT VS 5Y AVG
-4.34%
CURRENT VS 10Y AVG
+22.58%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-112.61%
vs the sector median at left
INmune Bio, Inc.
Market Cap
$49.71M
Return on Assets (ROA)
-68.60%
TTM Avg
-124.17%
3Y Avg
-83.59%
5Y Avg
-65.75%
Market Cap
$49.45M
Return on Assets (ROA)
-171.51%
TTM Avg
-144.24%
3Y Avg
-112.57%
5Y Avg
-82.33%
Market Cap
$49.25M
Return on Assets (ROA)
-11.23%
TTM Avg
-20.22%
3Y Avg
-14.66%
5Y Avg
-10.97%
Market Cap
$50.27M
Return on Assets (ROA)
-97.71%
TTM Avg
-228.91%
3Y Avg
-360.64%
5Y Avg
-295.62%
Market Cap
$50.28M
Return on Assets (ROA)
5.76%
TTM Avg
13.86%
3Y Avg
7.25%
5Y Avg
29.75%
Market Cap
$48.89M
Return on Assets (ROA)
-37.53%
TTM Avg
-1.93%
3Y Avg
9.94%
5Y Avg
4.69%
Market Cap
$48.77M
Return on Assets (ROA)
-68.93%
TTM Avg
-45.51%
3Y Avg
-54.02%
5Y Avg
-50.43%
Market Cap
$48.76M
Return on Assets (ROA)
-22.27%
TTM Avg
-102.93%
3Y Avg
-118.23%
5Y Avg
-95.88%
Market Cap
$48.53M
Return on Assets (ROA)
-162.93%
TTM Avg
-287.06%
3Y Avg
-300.16%
5Y Avg
-220.25%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| INmune Bio, Inc. (INMB) | $49.71M | -68.60% | -124.17% | -83.59% | -65.75% |
| Clene Inc. (CLNN)vs › | $49.45M | -171.51% | -144.24% | -112.57% | -82.33% |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.25M | -11.23% | -20.22% | -14.66% | -10.97% |
| Envoy Medical, Inc. (COCH)vs › | $50.27M | -97.71% | -228.91% | -360.64% | -295.62% |
| biote Corp. (BTMD)vs › | $50.28M | 5.76% | 13.86% | 7.25% | 29.75% |
| Sensus Healthcare, Inc. (SRTS)vs › | $48.89M | -37.53% | -1.93% | 9.94% | 4.69% |
| TELA Bio, Inc. (TELA)vs › | $48.77M | -68.93% | -45.51% | -54.02% | -50.43% |
| Microbot Medical Inc. (MBOT)vs › | $48.76M | -22.27% | -102.93% | -118.23% | -95.88% |
| Apollomics, Inc. (APLM)vs › | $48.53M | -162.93% | -287.06% | -300.16% | -220.25% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | -44.77% | -25.55% | -81.14% | -76.43% |
ROA
-68.6%
ROE
-90.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -141.98% |
| 2024-12-31 | -106.37% |
| 2023-12-31 | -52.64% |
| 2022-12-31 | -33.37% |
| 2021-12-31 | -30.36% |
| 2020-12-31 | -29.76% |
| 2019-12-31 | -31.38% |
| 2018-12-31 | -71.65% |
| 2017-12-31 | -4.51% |
| 2016-12-31 | -61.34% |
| 2015-12-31 | -411.28% |
